Coronary heart disease drug market to reach $19.4B by 2017
Although the Plavix and Lipitor patents expire in 2012, new drug launches will drive an increase of $4.6 billion in the overall coronary heart disease market by 2017, according to the pharmaceutical and healthcare research firm Decision Resources.
The report found that the market to treat coronary heart disease will grow from $14.8 billion in 2007 to $19.4 billion in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The researchers said that the growth will be driven by the launches of Eli Lilly/Daiichi Sankyo's Effient, AstraZeneca's Brilinta and Schering-Plough's SCH-530348, as well as the introduction of two new CETP inhibitors from Roche/Japan Tobacco and Merck.
Despite the patent expiries of the two sales-leading coronary heart disease therapies--Sanofi-Aventis and Bristol-Myers Squibb's Plavix and Pfizer's Lipitor--the market entry of fixed-dose combinations, with agents such as Abbott's Tricor, Solvay's Lipanthyl and Abbott's Niaspan, will also offset the negative impact of generic erosion, according to the report.
"Cardiologists' approach to coronary heart disease therapy has experienced a remarkable international convergence as optimal drug treatment for post-MI--the condition that accounts for more than 70 percent of coronary heart disease market sales--now consists of two antiplatelet agents, including aspirin, a statin, an ACE inhibitor and a beta blocker," said Nikhil Mehta, therapeutic area director at Decision Resources. "Multidrug therapy has also become routine in the treatment of stable angina. The arrival of novel agents will be welcomed by clinicians, particularly for high-risk patients, but some of these therapies could face market access and compliance hurdles."
The report found that the market to treat coronary heart disease will grow from $14.8 billion in 2007 to $19.4 billion in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The researchers said that the growth will be driven by the launches of Eli Lilly/Daiichi Sankyo's Effient, AstraZeneca's Brilinta and Schering-Plough's SCH-530348, as well as the introduction of two new CETP inhibitors from Roche/Japan Tobacco and Merck.
Despite the patent expiries of the two sales-leading coronary heart disease therapies--Sanofi-Aventis and Bristol-Myers Squibb's Plavix and Pfizer's Lipitor--the market entry of fixed-dose combinations, with agents such as Abbott's Tricor, Solvay's Lipanthyl and Abbott's Niaspan, will also offset the negative impact of generic erosion, according to the report.
"Cardiologists' approach to coronary heart disease therapy has experienced a remarkable international convergence as optimal drug treatment for post-MI--the condition that accounts for more than 70 percent of coronary heart disease market sales--now consists of two antiplatelet agents, including aspirin, a statin, an ACE inhibitor and a beta blocker," said Nikhil Mehta, therapeutic area director at Decision Resources. "Multidrug therapy has also become routine in the treatment of stable angina. The arrival of novel agents will be welcomed by clinicians, particularly for high-risk patients, but some of these therapies could face market access and compliance hurdles."